BioCareSD Grows Product Portfolio, Partners with UCB

BioCareSD, a specialty distributor of life-saving therapies, has signed a contract with UCB, a biopharma company, to add six new product offerings to its portfolio. The deal allows the distributor to cater to a wider patient population.

Available now via BioCareSD’s specialty distribution network, the six new products include:

• BRIVIACT: partial-onset seizures in patients one month of age and older
• CIMZIA: Crohn’s disease and rheumatoid arthritis
• NAYZILAM: intermittent, stereotypic episodes of frequent seizure activity, distinct from patient’s usual seizure pattern in patients with epilepsy 12 years of age and older
• NEUPRO: Parkinson’s disease and restless leg syndrome
• KEPPRA: partial-onset seizures in adults with epilepsy
• VIMPAT: partial-onset seizures in patients with epilepsy 17 years of age and older

“We are consistently looking for ways to better serve our customers and expand into patient populations whose needs are currently unmet,” says Andrew Kirk, chief revenue officer at BioCareSD. “This incredible opportunity to work with UCB has allowed us to increase patient access to much-needed and potentially life-saving therapeutics, which is of the utmost importance.”